Psychopharmacology
Section committee
MOHR Pavel
, Chair
Stuhec Matej,
Co-Chair
BARTOVA Lucie,
Secretary Section mission
This Section's mission is to:
Section's mission is to present the benefits and risks of psychopharmacological treatment of mental disorders. The main activities are based on general and clinical pharmacology and their association with clinical trials and prudent medication use in daily practice.
Section objectives
- To increase interest in psychopharmacology
- To present benefits and risks of psychopharmacological treatment
- To present newest psychopharmacological treatment
Annual reports
Future Activities
symposium
Psychopharmacology for depression and anxiety in the medically ill patient
08 April 2025 - 08 April 2025 / EPA Congress. The 33rd European Congress of Psychiatry, 05-08 April 2025, Madrid (Spain)
Description :
The symposium will address the management of anxiety and depressive symptoms in patients with primary somatic diseases, focusing on pharmacodynamics and pharmacokinetic issues of antidepressants, interactions with non-psychotropic medications, and integration with psychotherapeutic strategies. Presentations include clinical vignettes and case-based treatment recommendations.
Chairs: Diogo Telles Correia (Portugal), Pavel Mohr (Czech Republic)
Speakers:
15:00 - 15:17: Typical clinical manifestations of anxiety and depression in patients with medical illness and general notions about their treatment. Speaker: Lucie Bartova (Austria)
15:17 - 15:34: Psychopharmacological treatment of anxiety and depression in patients with diabetes. Pharmacodynamics and pharmacokinetic considerations, drug interactions. Speaker: Filipa Novais (Portugal)
15:34 - 15:51: Psychopharmacological treatment of anxiety and depression in patients with liver and/or kidney disease. Pharmacodynamics and pharmacokinetic considerations, drug interactions. Speaker: Matej Stuhec (Slovenia)
15:51 - 16:08: Psychopharmacological treatment of anxiety and depression in patients with cardiological disease. Pharmacodynamics and pharmacokinetic considerations, drug interactions. Speaker: Giorgio Mattei (Italy)
16:08 - 16:30: Q&A
Partners :
This session is jointly organized by the Sections on Consultation Liaison Psychiatry and Psychosomatics & Psychopharmacology
symposium
Therapeutic drug monitoring issues in clinical practice: from adulthood to elderly age
06 April 2025 - 06 April 2025 / EPA Congress. The 33rd European Congress of Psychiatry, 05-08 April 2025, Madrid (Spain)
Description :
Therapeutic drug monitoring (TDM) involves measuring drug concentrations in plasma and is a valuable method for individualizing doses in patients. This workshop will focus on the practical aspects of TDM use in clinical practice, particularly dose adjustments and recognizing drug-drug interactions. The structure includes a case presentation and audience interaction via tools like Mentimeter.
Chairs: Lucie Bartova (Austria), Cecile Hanon (France)
Speakers:
10:00 - 10:14: Therapeutic drug monitoring for mood stabilizers in elderly: a case report. Speaker: Georgios Schoretsanitis (Switzerland)
10:14 - 10:28: Pharmacokinetic background of therapeutic drug monitoring in this case. Speaker: Matej Stuhec (Slovenia)
10:28 - 10:42: Therapeutic drug monitoring in clozapine treatment. Speaker: Pavel Mohr (Czech Republic)
10:42 - 10:56: How to use therapeutic drug monitoring for comorbidities management in this case. Speaker: Jens Benninghoff (Germany)
10:56 - 11:10: Therapeutic drug monitoring and psychiatric curriculum based on the clinical cases. Speaker: István Bitter (Hungary)
11:10 - 11:30: Q&A
Partners :
This session is jointly organized by the Sections on Psychopharmacology & Old Age Psychiatry.
symposium
Are side effects needed for efficacy in psychiatric treatments?
06 April 2025 - 06 April 2025 / EPA Congress. The 33rd European Congress of Psychiatry, 05-08 April 2025, Madrid (Spain)
Description :
This session is organized by the Section on Psychopharmacology. Since the introduction of the first psychotropic drugs into clinical practice, psychiatrists have struggled to find the optimum balance between wanted and unwanted effects. This symposium critically examines the relationship between therapeutic and adverse effects of psychotropics in treating various mental disorders, including depression, schizophrenia, and substance use disorders.
Chairs: Lucie Bartova (Austria), Pavel Mohr (Czech Republic)
Speakers:
08:00 - 08:17: Cardiovascular and metabolic side effects of antipsychotic treatment in schizophrenia: What comes first? Speaker: Peter Falkai (Germany)
08:17 - 08:34: Are side effects necessary for antidepressant treatment? Speaker: Siegfried Kasper (Austria)
08:34 - 08:51: What about the trip? The relationship between ketamine’s acute and antidepressant effect. Speaker: Veronika Andrashko (Czech Republic)
08:51 - 09:08: Who wants side effects on Substance Use Disorder's treatment? Speaker: Jose Antoni Ramos-Quiroga (Spain)
09:08 - 09:30: Q&A
other meetings
Section Webinar: Evidence-Based Diagnosis and Treatment of Treatment-Resistant Depression – Update and Preview
27 October 2025 - 27 October 2025 / Online
Description :
Webinar Overview: Major depressive disorder (MDD) is a common psychiatric condition with a significant subset of patients experiencing treatment-resistant depression (TRD). The webinar will address diagnostic challenges, including the exclusion of pseudoresistance, and provide an overview of evidence-based pharmacological and non-pharmacological treatments, including innovative approaches.
- Moderators: Lucie Bartova, Siegfried Kasper
- Speakers: Georg Kranz, Pia Baldinger-Melich, Christoph Kraus
- Duration: 90 minutes, including a Q&A session.
- Target Audience: Clinical Psychiatrists and Neuroscientists at all career stages.